Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21709483 | 0.95 | KMT2A (0.38) | ALOX5MEN1KMT2AATMNUDT1 | |
| SCHEMBL21709469 | 0.95 | KMT2A (0.38) | ALOX5MEN1KMT2AATMNUDT1 | |
| SCHEMBL21709314 | 0.94 | KMT2A (0.37) | ALOX5MEN1KMT2AATMMAPT | |
| SCHEMBL21709224 | 0.92 | ALOX5 (0.34) | ALOX5MEN1KMT2AATM | |
| SCHEMBL21709332 | 0.92 | KMT2A (0.38) | ALOX5MEN1KMT2AATMNUDT1 | |
| SCHEMBL21709369 | 0.92 | NUDT1 (0.36) | ALOX5NUDT1 | |
| SCHEMBL21709336 | 0.91 | ALOX5 (0.32) | ALOX5MEN1KMT2AATM | |
| SCHEMBL21709479 | 0.91 | KMT2A (0.37) | MEN1KMT2AATMMAPT | |
| SCHEMBL21709472 | 0.90 | MEN1 (0.32) | MEN1KMT2AATMNUDT1 | |
| SCHEMBL21709226 | 0.89 | MEN1 (0.39) | MEN1KMT2AATMNUDT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048207-A1 | COMPOUNDS WITH ARYLAMINE STRUCTURES | MERCK PATENT GMBH (DE) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048207-A1 | COMPOUNDS WITH ARYLAMINE STRUCTURES | DDT, NAT1, INMT | ALOX5 3104/4885MEN1 2014/4885KMT2A 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.